Home » Stocks » BDSX

Biodesix, Inc. (BDSX)

Stock Price: $14.24 USD 0.12 (0.85%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $14.39 +0.15 (1.05%) May 7, 5:59 PM
Market Cap 387.30M
Revenue (ttm) 45.56M
Net Income (ttm) -31.35M
Shares Out 26.86M
EPS (ttm) -6.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $14.24
Previous Close $14.12
Change ($) 0.12
Change (%) 0.85%
Day's Open 14.12
Day's Range 13.78 - 15.00
Day's Volume 65,043
52-Week Range 10.85 - 31.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, has announced their plan to add ...

1 week ago - Business Wire

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced in partnership w...

1 week ago - Business Wire

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will rel...

1 week ago - Business Wire

BOULDER, Colo.--(BUSINESS WIRE)-- #patientsfirst--Pulmonary disease expert, Dr. Susan Garwood, is hosted by CHEST to discuss standardized risk assessment to inform lung nodule management

2 weeks ago - Business Wire

BOULDER, Colo.--(BUSINESS WIRE)-- #patientsfirst--Biodesix releases new data at AACR annual meeting on the use of proteomic profiling to help guide physician treatment strategies for NSCLC patients.

3 weeks ago - Business Wire

BOULDER, Colo.--(BUSINESS WIRE)-- #patientsfirst--Biodesix receives two important U.S. patents for diagnostic methods, which seek to improve care for cancer patients.

1 month ago - Business Wire

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix announces the closing of a $30 million term loan.

1 month ago - Business Wire

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix releases fourth quarter and full year 2020 results

1 month ago - Business Wire

BOULDER, Colo.--(BUSINESS WIRE)-- #BDSX--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial re...

1 month ago - Business Wire

BOULDER, Colo.--(BUSINESS WIRE)-- #BDSX--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that The Healthcare Technology Re...

2 months ago - Business Wire

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the company has partnered with Chica...

2 months ago - Business Wire

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that management will participate in two u...

2 months ago - Business Wire

BOULDER, Co.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced a publication describing the development of...

2 months ago - Business Wire

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that Chief Executive Officer Scott Hutton...

3 months ago - Business Wire

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that three abstracts from multiple clinic...

3 months ago - Business Wire

NEW YORK & BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX) today announced an agreement with HiberCell, a biotechnology company developing novel therapeutics for cancer relapse and metast...

3 months ago - Business Wire

The IPO market is taking a break during the shortened Thanksgiving week, with just one IPO and two SPACs scheduled to raise $900 million. Russian e-commerce company Ozon Holdings plans to raise $750 mil...

Other stocks mentioned: ALGM, AVIR, GATO, GLTO, LESL, LU, MAX ...
5 months ago - Seeking Alpha

Biodesix has gone public in an offering which was not well-received by the market. Lack of growth and steep losses make investors rightfully cautious based on the conditions as they are today.

6 months ago - Seeking Alpha

About BDSX

Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests that provide physicians with timely results to facilitate treatment decisions. It also provides Bio-Rad SARS-CoV-2 ddPCR test, which is designed to detect the presence of infection by ... [Read more...]

Industry
Diagnostics & Research
IPO Date
Oct 28, 2020
Stock Exchange
NASDAQ
Ticker Symbol
BDSX
Full Company Profile

Financial Performance

In 2020, Biodesix's revenue was $45.56 million, an increase of 85.55% compared to the previous year's $24.55 million. Losses were -$31.35 million, 2.03% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Biodesix stock is "Strong Buy." The 12-month stock price forecast is 28.00, which is an increase of 96.63% from the latest price.

Price Target
$28.00
(96.63% upside)
Analyst Consensus: Strong Buy